2026 AOAO Annual Fall Meeting

Gaylord Pacific Resort, Chula Vista CA
October 29-31, 2026

EXHIBITORS and SPONSORS

Plan to visit the exhibits! The Exhibits provide each attendee an opportunity to engage with exhibitors to learn about state-of-the-art medical products and services.

Exhibit Schedule

Thursday, October 29, 2026
6:30 – 7:30 am	Breakfast with Exhibitors
9:00 – 10:00 am	Coffee Break with Exhibitors
12:00 – 1:00 pm	Lunch with Exhibitors
2:35 – 3:05 pm	Coffee Break with Exhibitors
3:55 - 4:10 pm	Coffee Break with Exhibitors
5:30 – 6:30 pm	Reception with Exhibitors

Friday, October 30, 2026
6:00 – 7:00 am	Breakfast with Exhibitors
8:30 – 9:00 am	Coffee Break with Exhibitors
9:25 - 10:00 am	Coffee Break with Exhibitors
11:30 am – 12:30 pm	Lunch with Exhibitors

For Exhibit and Sponsorship information go to https://aoao.org/promotions-information/annual-fall/

Click on the exhibitor/sponsor logo to view more information on the organization's website.

Gold Exhibitor

	Kotlar Cohen Trial Attorneys was built on decades of experience in Workers’ Compensation, PIP, and medical reimbursement. Today, we combine that foundation with the advocacy of seasoned, Board-Certified Trial Attorneys to aggressively represent healthcare providers in Federal No Surprises Act (NSA) arbitrations nationwide. Our Federal NSA practice has one primary objective: recovering the revenue healthcare providers have earned. From the Open Negotiation period through Federal IDR arbitration and post-award payment collection efforts, our team handles the process from start to finish—challenging underpayments, crafting strong legal arguments to build arbitration cases, and pursuing the reimbursement our clients deserve. Transparency is fundamental to how we represent our clients. Providers are kept informed throughout the entire process, with clear insight into case status, arbitration progress, outcomes, and recovery efforts. No wondering where a case stands. Our clients know what we are doing, where their cases are, and what comes next. You focus on your patients. We fight for your reimbursement.

Kotlar Cohen Trial Attorneys was built on decades of experience in Workers’ Compensation, PIP, and medical reimbursement. Today, we combine that foundation with the advocacy of seasoned, Board-Certified Trial Attorneys to aggressively represent healthcare providers in Federal No Surprises Act (NSA) arbitrations nationwide.

Our Federal NSA practice has one primary objective: recovering the revenue healthcare providers have earned.

From the Open Negotiation period through Federal IDR arbitration and post-award payment collection efforts, our team handles the process from start to finish—challenging underpayments, crafting strong legal arguments to build arbitration cases, and pursuing the reimbursement our clients deserve.

Transparency is fundamental to how we represent our clients. Providers are kept informed throughout the entire process, with clear insight into case status, arbitration progress, outcomes, and recovery efforts. No wondering where a case stands. Our clients know what we are doing, where their cases are, and what comes next.

You focus on your patients. We fight for your reimbursement.

Silver Exhibitor

	DePuy Synthes provides one of the most comprehensive orthopaedics portfolios in the world that helps heal and restore movement for the millions of patients we serve. DePuy Synthes solutions, in specialties including joint reconstruction, trauma, extremities, craniomaxillofacial, spinal surgery and sports medicine, in addition to the VELYS™ Enabling Tech portfolio, are designed to advance patient care while delivering clinical and economic value.

DePuy Synthes provides one of the most comprehensive orthopaedics portfolios in the world that helps heal and restore movement for the millions of patients we serve. DePuy Synthes solutions, in specialties including joint reconstruction, trauma, extremities, craniomaxillofacial, spinal surgery and sports medicine, in addition to the VELYS™ Enabling Tech portfolio, are designed to advance patient care while delivering clinical and economic value.

	Shoulder Innovations develops leading edge shoulder arthroplasty technology. The InSet™ Shoulder System, is a fully integrated anatomic and reverse system featuring the InSet™ glenoid, a game-changing design backed by long term data. Please visit our exhibit to learn more. www.shoulderinnovations.com

Shoulder Innovations develops leading edge shoulder arthroplasty technology. The InSet™ Shoulder System, is a fully integrated anatomic and reverse system featuring the InSet™ glenoid, a game-changing design backed by long term data. Please visit our exhibit to learn more. www.shoulderinnovations.com

	About Zimmer Biomet Zimmer Biomet focuses on alleviating pain and improving the quality of life for people around the world through its innovative, collaborative ecosystem of outstanding products and solutions. As a trusted partner, Zimmer Biomet strives to deliver optimal clinical and economical outcomes in musculoskeletal health. Founded in 1927 and headquartered in Warsaw, Indiana, USA, Zimmer Biomet is a global leader in musculoskeletal healthcare. We design, manufacture and market orthopaedic reconstructive products sports medicine, biologics, extremities and trauma products; craniomaxillofacial and thoracic products; and related surgical products. We collaborate with healthcare professionals around the globe to advance the pace of innovation. Our products and solutions help treat patients suffering from disorders of, or injuries to, bones, joints or supporting soft tissues. Together with healthcare professionals, we help millions of people live better lives. We have operations in more than 25 countries around the world and sell products in more than 100 countries.

About Zimmer Biomet

Zimmer Biomet focuses on alleviating pain and improving the quality of life for people around the world through its innovative, collaborative ecosystem of outstanding products and solutions. As a trusted partner, Zimmer Biomet strives to deliver optimal clinical and economical outcomes in musculoskeletal health.

Founded in 1927 and headquartered in Warsaw, Indiana, USA, Zimmer Biomet is a global leader in musculoskeletal healthcare. We design, manufacture and market orthopaedic reconstructive products sports medicine, biologics, extremities and trauma products; craniomaxillofacial and thoracic products; and related surgical products. We collaborate with healthcare professionals around the globe to advance the pace of innovation. Our products and solutions help treat patients suffering from disorders of, or injuries to, bones, joints or supporting soft tissues. Together with healthcare professionals, we help millions of people live better lives. We have operations in more than 25 countries around the world and sell products in more than 100 countries.

Bronze Exhibitor

	Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.

Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.

	Enovis Corporation (NYSE: ENOV) is an innovation-driven medical technology growth company dedicated to developing clinically differentiated solutions that generate measurably better patient outcomes and transform workflows. Powered by a culture of continuous improvement, global talent and innovation, the Company’s extensive range of products, services and integrated technologies fuel active lifestyles in orthopedics and beyond. For more information about Enovis, please visit www.enovis.com.

Enovis Corporation (NYSE: ENOV) is an innovation-driven medical technology growth company dedicated to developing clinically differentiated solutions that generate measurably better patient outcomes and transform workflows. Powered by a culture of continuous improvement, global talent and innovation, the Company’s extensive range of products, services and integrated technologies fuel active lifestyles in orthopedics and beyond. For more information about Enovis, please visit www.enovis.com.

	Stryker is a global leader in medical technologies and, together with our customers, we are driven to make healthcare better. We offer innovative products and services in MedSurg, Neurotechnology and Orthopaedics that help improve patient and healthcare outcomes.

Stryker is a global leader in medical technologies and, together with our customers, we are driven to make healthcare better. We offer innovative products and services in MedSurg, Neurotechnology and Orthopaedics that help improve patient and healthcare outcomes.

Exhibitor

	The American Orthopaedic Foot & Ankle Society® (AOFAS) mobilizes our dynamic community of foot and ankle orthopaedic surgeons to improve patient care through education, research, and advocacy. As the premier global organization for foot and ankle care, AOFAS delivers exceptional events and resources for continuous education, funds and promotes innovative research, and broadens patient understanding of foot and ankle conditions and treatments. By emphasizing collaboration and excellence, AOFAS inspires ever-increasing levels of professional performance leading to improved patient outcomes. About Foot and Ankle Orthopaedic Surgeons Foot and Ankle Orthopaedic Surgeons are medical doctors who specialize in the diagnosis and treatment of injuries, diseases, and other conditions of the foot and ankle. Their comprehensive education and training include four years of medical school, five years of residency training in orthopaedic surgery, and a one- or two-year fellowship focused on foot and ankle care. No other healthcare provider has the depth and breadth of experience to treat the full spectrum of foot and ankle conditions.

The American Orthopaedic Foot & Ankle Society® (AOFAS) mobilizes our dynamic community of foot and ankle orthopaedic surgeons to improve patient care through education, research, and advocacy. As the premier global organization for foot and ankle care, AOFAS delivers exceptional events and resources for continuous education, funds and promotes innovative research, and broadens patient understanding of foot and ankle conditions and treatments. By emphasizing collaboration and excellence, AOFAS inspires ever-increasing levels of professional performance leading to improved patient outcomes.

About Foot and Ankle Orthopaedic Surgeons

Foot and Ankle Orthopaedic Surgeons are medical doctors who specialize in the diagnosis and treatment of injuries, diseases, and other conditions of the foot and ankle. Their comprehensive education and training include four years of medical school, five years of residency training in orthopaedic surgery, and a one- or two-year fellowship focused on foot and ankle care. No other healthcare provider has the depth and breadth of experience to treat the full spectrum of foot and ankle conditions.

	Biocomposites is an international medical device company that engineers, manufactures and markets world leading products for use in infection management. Based in Keele, UK with operations around the world, Biocomposites is a leading developer of innovative calcium compounds and specialty polymer products for surgical use. Today our products are used in over 1 million procedures every year.

Biocomposites is an international medical device company that engineers, manufactures and markets world leading products for use in infection management. Based in Keele, UK with operations around the world, Biocomposites is a leading developer of innovative calcium compounds and specialty polymer products for surgical use. Today our products are used in over 1 million procedures every year.

	CONMED is a global medical technology company that specializes in surgical products and services that allow our physician customers to deliver high quality care. It’s our mission to enable healthcare providers around the world to deliver exceptional outcomes for patients through accessible CONMED solutions.

CONMED is a global medical technology company that specializes in surgical products and services that allow our physician customers to deliver high quality care.

It’s our mission to enable healthcare providers around the world to deliver exceptional outcomes for patients through accessible CONMED solutions.

	Every year, there are more than 186,000 pelvic fractures in the U.S. Traditional treatment options for these injuries have inherent limitations. The CurvaFix IM Implant utilizes interlocking, high-strength components to follow and fill complex, non-linear bone corridors, ensuring a solid and reliable intramedullary fracture repair. The procedure can be completed in as little as 20 minutes and is intended to provide safe and strong fixation – helping to reduce pain and increasing the likelihood of early mobility and faster recovery for patients. To learn more about CurvaFix visit our website: www.curvafix.com *data on file

Every year, there are more than 186,000 pelvic fractures in the U.S. Traditional treatment options for these injuries have inherent limitations. The CurvaFix IM Implant utilizes interlocking, high-strength components to follow and fill complex, non-linear bone corridors, ensuring a solid and reliable intramedullary fracture repair. The procedure can be completed in as little as 20 minutes and is intended to provide safe and strong fixation – helping to reduce pain and increasing the likelihood of early mobility and faster recovery for patients.

To learn more about CurvaFix visit our website: www.curvafix.com

*data on file

	Maxx Orthopedics develops and manufactures innovative joint replacement products designed to address the needs of today's diverse patient population. At Maxx Orthopedics, our goal is to help patients Pursue Life®. Our focus is knee and hip replacement solutions for both hospitals and outpatient surgery centers through our key product lines: Freedom Knee®, Libertas Hip® and our outpatient solutions - QRS® (Quick Recovery Solutions).

Maxx Orthopedics develops and manufactures innovative joint replacement products designed to address the needs of today's diverse patient population. At Maxx Orthopedics, our goal is to help patients Pursue Life®. Our focus is knee and hip replacement solutions for both hospitals and outpatient surgery centers through our key product lines: Freedom Knee®, Libertas Hip® and our outpatient solutions - QRS® (Quick Recovery Solutions).

	Miach Orthopaedics is leading a shift in the treatment of anterior cruciate ligament tears from reconstruction to restoration. The company’s Bridge-Enhanced ACL Restoration (BEAR) Implant is the first medical technology to demonstrate with Level 1 clinical evidence that it enables the body to heal its own torn ACL. Unlike reconstruction, the BEAR Implant does not require a second surgical wound site to remove a healthy tendon from another part of the leg or the use of a donor tendon. The BEAR Implant is an ideal bridge designed to restore the native ACL. Autologous whole blood is combined with the BEAR Implant to form a clot that bridges the gap between the torn ends of the ACL and protects the clot from the harsh synovial environment. The BEAR Implant facilitates the body's own healing response by supporting cell migration and proliferation. Within eight weeks, the BEAR Implant is resorbed and replaced with native cells, collagen and blood vessels, and the new tissue continues to remodel and strengthen over time. The BEAR Implant is indicated for a broad range of tear types and is implanted with an easy, bone-sparing technique.

Miach Orthopaedics is leading a shift in the treatment of anterior cruciate ligament tears from reconstruction to restoration. The company’s Bridge-Enhanced ACL Restoration (BEAR) Implant is the first medical technology to demonstrate with Level 1 clinical evidence that it enables the body to heal its own torn ACL. Unlike reconstruction, the BEAR Implant does not require a second surgical wound site to remove a healthy tendon from another part of the leg or the use of a donor tendon. The BEAR Implant is an ideal bridge designed to restore the native ACL. Autologous whole blood is combined with the BEAR Implant to form a clot that bridges the gap between the torn ends of the ACL and protects the clot from the harsh synovial environment. The BEAR Implant facilitates the body's own healing response by supporting cell migration and proliferation. Within eight weeks, the BEAR Implant is resorbed and replaced with native cells, collagen and blood vessels, and the new tissue continues to remodel and strengthen over time. The BEAR Implant is indicated for a broad range of tear types and is implanted with an easy, bone-sparing technique.

	OSSIOfiber® is the first-of-its kind implant material to securely fixate and fully integrate into the native anatomy with nothing left behind. Unlike other implants, OSSIOfiber® contains the same natural minerals found in bones themselves, but it’s stronger—it eventually becomes part of the bone, encouraging a return to full strength naturally without the risks and costs associated with permanent hardware.1 1. Data on file at OSSIO

OSSIOfiber® is the first-of-its kind implant material to securely fixate and fully integrate into the native anatomy with nothing left behind.

Unlike other implants, OSSIOfiber® contains the same natural minerals found in bones themselves, but it’s stronger—it eventually becomes part of the bone, encouraging a return to full strength naturally without the risks and costs associated with permanent hardware.1

1. Data on file at OSSIO

	Premia Spine is a spine technology company focused on redefining the standard of care in lumbar degenerative conditions. Through our motion-preserving TOPS™ System, we provide surgeons with an alternative to fusion that stabilizes the spine while maintaining segmental motion. Backed by robust clinical data and years of global experience, our technology is designed to address the challenges of lumbar stenosis with spondylolisthesis while supporting patient mobility and long-term outcomes.

Premia Spine is a spine technology company focused on redefining the standard of care in lumbar degenerative conditions. Through our motion-preserving TOPS™ System, we provide surgeons with an alternative to fusion that stabilizes the spine while maintaining segmental motion.

Backed by robust clinical data and years of global experience, our technology is designed to address the challenges of lumbar stenosis with spondylolisthesis while supporting patient mobility and long-term outcomes.

	Smith+Nephew is a global medical technology business with global leadership positions in Orthopaedic Reconstruction, Sports Medicine, Trauma Fixation, Extremities & Limb Restoration, and Advanced Wound Management. Visit www.smith-nephew.com for more information.

Smith+Nephew is a global medical technology business with global leadership positions in Orthopaedic Reconstruction, Sports Medicine, Trauma Fixation, Extremities & Limb Restoration, and Advanced Wound Management. Visit www.smith-nephew.com for more information.

	#1 in Orthopedic Surgicalist Programs - An Innovative Team-Based Approach to Care As the visionaries of the Surgicalist Model, our Orthopedic, Trauma, General Surgery and Urology programs are built to align the goals of both healthcare leaders and clinicians to support hospitals and practices for the long-term. Unlike temporary locums staffing fixes, our Surgicalist programs are a long-term solution – designed to better meet the lifestyle expectations of clinicians today while providing consistent staffing and call coverage. Active members of a hospital’s medical staff, our Surgicalists work with hospital leadership, are members of coordinated teams, they serve on committees, and are clinical leaders in the local communities they serve.

#1 in Orthopedic Surgicalist Programs - An Innovative Team-Based Approach to Care

As the visionaries of the Surgicalist Model, our Orthopedic, Trauma, General Surgery and Urology programs are built to align the goals of both healthcare leaders and clinicians to support hospitals and practices for the long-term.

Unlike temporary locums staffing fixes, our Surgicalist programs are a long-term solution – designed to better meet the lifestyle expectations of clinicians today while providing consistent staffing and call coverage.

Active members of a hospital’s medical staff, our Surgicalists work with hospital leadership, are members of coordinated teams, they serve on committees, and are clinical leaders in the local communities they serve.

	United Specialists MSO is a physician-focused management services organization dedicated to supporting practices through comprehensive administrative, operational, financial, and business solutions. We partner with physicians to streamline practice operations, strengthen performance, and support sustainable growth—allowing providers to focus on delivering exceptional patient care. Our team brings expertise in practice management, revenue cycle support, payer relations, compliance, and strategic business development to help orthopedic practices thrive in today’s evolving healthcare environment.

United Specialists MSO is a physician-focused management services organization dedicated to supporting practices through comprehensive administrative, operational, financial, and business solutions. We partner with physicians to streamline practice operations, strengthen performance, and support sustainable growth—allowing providers to focus on delivering exceptional patient care. Our team brings expertise in practice management, revenue cycle support, payer relations, compliance, and strategic business development to help orthopedic practices thrive in today’s evolving healthcare environment.

	Vericel develops, manufactures, and markets autologous cell-based therapies for patients with serious diseases and conditions. The company markets MACI® (autologous cultured chondrocytes on porcine collagen membrane), a third generation autologous cellularized scaffold product that is indicated for the repair of single or multiple symptomatic, full-thickness cartilage defects of the adult knee, with or without bone involvement.

Vericel develops, manufactures, and markets autologous cell-based therapies for patients with serious diseases and conditions. The company markets MACI® (autologous cultured chondrocytes on porcine collagen membrane), a third generation autologous cellularized scaffold product that is indicated for the repair of single or multiple symptomatic, full-thickness cartilage defects of the adult knee, with or without bone involvement.

	About Vertex Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases. The company has approved medicines that treat the underlying causes of multiple chronic, life-shortening genetic diseases — cystic fibrosis, sickle cell disease and transfusion-dependent beta thalassemia — and continues to advance clinical and research programs in these diseases. Vertex also has a robust clinical pipeline of investigational therapies across a range of modalities in other serious diseases where it has deep insight into causal human biology, including acute and neuropathic pain, APOL1-mediated kidney disease, IgA nephropathy, autosomal dominant polycystic kidney disease, type 1 diabetes, myotonic dystrophy type 1 and alpha-1 antitrypsin deficiency. Vertex was founded in 1989 and has its global headquarters in Boston, with international headquarters in London. Additionally, the company has research and development sites and commercial offices in North America, Europe, Australia, Latin America and the Middle East. Vertex is consistently recognized as one of the industry's top places to work, including 14 consecutive years on Science magazine's Top Employers list and one of Fortune’s 100 Best Companies to Work For. For company updates and to learn more about Vertex's history of innovation, visit www.vrtx.com or follow us on LinkedIn, Facebook, Instagram, YouTube and Twitter/X.

About Vertex

Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases. The company has approved medicines that treat the underlying causes of multiple chronic, life-shortening genetic diseases — cystic fibrosis, sickle cell disease and transfusion-dependent beta thalassemia — and continues to advance clinical and research programs in these diseases. Vertex also has a robust clinical pipeline of investigational therapies across a range of modalities in other serious diseases where it has deep insight into causal human biology, including acute and neuropathic pain, APOL1-mediated kidney disease, IgA nephropathy, autosomal dominant polycystic kidney disease, type 1 diabetes, myotonic dystrophy type 1 and alpha-1 antitrypsin deficiency.

Vertex was founded in 1989 and has its global headquarters in Boston, with international headquarters in London. Additionally, the company has research and development sites and commercial offices in North America, Europe, Australia, Latin America and the Middle East. Vertex is consistently recognized as one of the industry's top places to work, including 14 consecutive years on Science magazine's Top Employers list and one of Fortune’s 100 Best Companies to Work For. For company updates and to learn more about Vertex's history of innovation, visit www.vrtx.com or follow us on LinkedIn, Facebook, Instagram, YouTube and Twitter/X.

Corporate Showcase Sponsor

	Smith+Nephew is a global medical technology business with global leadership positions in Orthopaedic Reconstruction, Sports Medicine, Trauma Fixation, Extremities & Limb Restoration, and Advanced Wound Management. Visit www.smith-nephew.com for more information.

	About Vertex Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases. The company has approved medicines that treat the underlying causes of multiple chronic, life-shortening genetic diseases — cystic fibrosis, sickle cell disease and transfusion-dependent beta thalassemia — and continues to advance clinical and research programs in these diseases. Vertex also has a robust clinical pipeline of investigational therapies across a range of modalities in other serious diseases where it has deep insight into causal human biology, including acute and neuropathic pain, APOL1-mediated kidney disease, IgA nephropathy, autosomal dominant polycystic kidney disease, type 1 diabetes, myotonic dystrophy type 1 and alpha-1 antitrypsin deficiency. Vertex was founded in 1989 and has its global headquarters in Boston, with international headquarters in London. Additionally, the company has research and development sites and commercial offices in North America, Europe, Australia, Latin America and the Middle East. Vertex is consistently recognized as one of the industry's top places to work, including 14 consecutive years on Science magazine's Top Employers list and one of Fortune’s 100 Best Companies to Work For. For company updates and to learn more about Vertex's history of innovation, visit www.vrtx.com or follow us on LinkedIn, Facebook, Instagram, YouTube and Twitter/X.

About Vertex